Publique en esta revista
Información de la revista
Vol. 35. Núm. S1.
Recomendaciones para el Soporte Nutricional del paciente crítico
Páginas 53-56 (Noviembre 2011)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 35. Núm. S1.
Recomendaciones para el Soporte Nutricional del paciente crítico
Páginas 53-56 (Noviembre 2011)
Acceso a texto completo
Recomendaciones para el soporte nutricional y metabólico especializado del paciente crítico. Actualización. Consenso SEMICYUC-SENPE: Paciente oncohematológico
Guidelines for specialized nutritional and metabolic support in the critically-ill patient. Update. Consensus of the Spanish Society of Intensive Care Medicine and Coronary Units-Spanish Society of Parenteral and Enteral Nutrition (SEMICYUC-SENPE): Oncohematological patient
Visitas
...
M. Planasa,??
Autor para correspondencia
mplanasvila@gmail.com

Autor para correspondencia.
, J.F. Fernández-Ortegab, J. Abilésc
a Escuela de Ciencias de La Salud, Universidad de Vic, Barcelona, España
b Hospital Regional Universitario Carlos Haya, Málaga, España
c Hospital Costa del Sol, Marbella, Málaga, España
Información del artículo
Resumen
Bibliografía
Descargar PDF
Estadísticas
Resumen

Los pacientes portadores de cáncer, en cualquier fase de su evolución, pueden precisar ingreso en UCI como consecuencia de complicaciones secundarias a su enfermedad de base o de las terapias quirúrgicas o farmacológicas a que se ven sometidos para tratar su enfermedad. La propia enfermedad cancerosa, así como el estado crítico a que pueden derivar como consecuencia de las complicaciones sobreañadidas, con frecuencia condicionan un alto grado de hipermetabolismo y de déficit de ingesta nutricional, lo que conduce en estos enfermos a una alta incidencia de desnutrición. Además, la propia enfermedad cancerosa condiciona una utilización anómala de los sustratos nutritivos, lo que podría condicionar una vía de administración y una proporción y aporte de nutrientes algo diferenciado de los pacientes no tumorales.

Palabras clave:
Cáncer
Farmaconutrientes
Glutamina
Abstract

Patients with cancer, irrespective of the stage of their disease, can require admission to the intensive care unit as a result of the complications of their underlying process or the surgical or pharmacological treatment provided. The cancer itself, as well as the critical status that can result from the complications of the disease, frequently lead to a high degree of hypermetabolism and inadequate energy intake, causing a high incidence of malnutrition in these patients. Moreover, cancer causes anomalous use of nutritional substrates and therefore the route of administration and proportion and intake of nutrients may differ in these patients from those in non-cancer patients.

Keywords:
Cancer
Pharmaconutrients
Glutamine
El Texto completo está disponible en PDF
Bibliografía
[1.]
J.R. Lieffers, M. Mourtzakis, K.D. Hall, L.J. McCargar, M.M. Prado, V.E. Baracos.
A visceral driven cachexia syndrome in patients with advanced colorectal cancer: contributions of organ and tumor mass to whole-body energy demands.
Am J Clin Nutr, 89 (2009), pp. 1173-1179
[2.]
M.J. Tisdale.
Cachexia in cancer patients.
Nat Rev Cancer, 2 (2002), pp. 862-871
[3.]
S.D. Zuijdgeest-van Leeuwen, J.W. Van den Berg, J.L. Wattimena, A. Van der Gaast, G.R. Swart, J.H. Wilson, et al.
Lipolysis and lipid oxidation in weight-losing cancer patients and healthy subjects.
Metabolism, 49 (2000), pp. 931-936
[4.]
J. Körber, S. Pricelius, M. Heidrich, M.J. Müller.
Increased lipid utilization in weight losing stable cancer patients with normal body weight.
Eur J Clin Nutr, 53 (1999), pp. 740-745
[5.]
A.S. Detsky, J.R. McLaughlin, J.P. Baker, N. Johnston, S. Whittaker, R.A. Mendelson, et al.
What is subjective global assessment of nutritional status?.
JPEN J Parenter Enteral Nutr, 11 (1987), pp. 8-13
[6.]
D. Gupta, C.A. Lammersfeld, P.G. Vashi, J. Burrows, C.G. Lis, J.F. Grutsch.
Prognostic significance of subjective global assessment (SGA) in advanced colorectal cancer.
Eur J Clin Nutr, 59 (2005), pp. 35-40
[7.]
M.R. Marques de Oliveira, K.C. Pagotto Fogaça, M. Escobar Gimenes Perencin, V.A. Leandro Merhi.
Subjective aspects of the nutritional status and length of chemotherapy treatment in patients with neoplasias.
Nutr Hosp, 25 (2010), pp. 126
[8.]
A.W. Moses, C. Slater, T. Preston, M.D. Barber, K.C. Fearon.
Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids.
Br J Cancer, 90 (2004), pp. 996-1002
[9.]
E. Gibney, M. Elia, S.A. Jeeb, P. Murgatroyd, G. Jennings.
Total energy expenditure in patients with samall-cell lung cancer: results of a validated study using the bicarbonate-urea method.
Metabolism, 46 (1997), pp. 1412-1417
[10.]
E.W. Fredrix, P.B. Soeters, E.F. Wouters, I.M. Deerenberg, M.F. Von Meyenfieldt, W.H. Saris.
Effects of different tumor type on resting energy expenditure.
Cancer Res, 51 (1991), pp. 6138-6141
[11.]
V. Chamouard Cogoluenhes, C. Chambrier, M. Michallet, B. Gordiani, J.Y. Ranchere, D. Combret, et al.
Energy expenditure during allogenic and autologus bone marrow transplantation.
Clin Nutr, 17 (1998), pp. 253-257
[12.]
G. Nitenberg, B. Raynard.
Nutritional support of the cancer patient: issues and dilemmas.
Crit Rev Oncol Hematol, 34 (2000), pp. 137-168
[13.]
A.J. McGeer, A.S. Detsky, K. O’Rourke.
Parenteral nutrition in cancer patients undergoing chemotherapy: a meta-analysis.
Nutrition, 6 (1990), pp. 233-240
[14.]
F. Bozzetti, L. Giannotti, M. Braga, V. Di Carlo, L. Mariani.
Postoperative complications in gastrointestinal cáncer patients: The joint role of the nutritional status and the nutritional support.
Clin Nutr, 26 (2007), pp. 698-709
[15.]
F. Bozzetti, M. Braga, L. Gianotti, C. Gavazzi, L. Mariani.
Postoperative enteral nutrition versus parenteral nutrition in malnourished patients with gastrointestinal cáncer: a randomized multicentre trial.
Lancet, 358 (2001), pp. 1487-1492
[16.]
K.E. Ohrn, Y.B. Wahlin, P.O. Sjödén.
Oral status during radiotherapy and chemotherapy: a descriptive study of patient experiences and the occurrence of oral complications.
Support Care Cancer, 9 (2001), pp. 247-257
[17.]
M. Gonzalo Marín, M.J. Tapia, F. García Torres, G. Olveira Fuster, M. Lainez López.
Evolución de parámetros antropométricos y nutricionales en pacientes con carcinoma de cabeza y cuello con gastrostomía percutánea.
Nutr Hosp, 25 (2010), pp. 45-46
[18.]
F. Bozzetti, C. Gavazzi, L. Mariani, F. Crippa.
Glucosa-based total parenteral nutrition does not stimulate glucosa uptake by humans tumours.
Clin Nutr, 23 (2004), pp. 417-421
[19.]
H. Takatsuka, Y. Takemoto, N. Iwata, A. Suehiro, T. Hamano, T. Okamoto, et al.
Oral eicosapentaenoic acid for complications of bone marrow transplantation.
Bone Marrow Transplant, 28 (2001), pp. 769-774
[20.]
A. Dewey, C. Baughan, T. Dean, B. Higgins, I. Jonson.
Eicosapentaenoic acid (EPA, an omega-3 fatty acid from fish oils) for the treatment of cancer cachexia.
Cochrane Database Syst Rev, (2007), pp. CD004597
[21.]
M. Elia, M.A. Van Bokhorst-de van der Schueren, J. Garvey, A. Goedhart, K. Lundholm, G. Nitenberg, et al.
Enteral (oral or tube administration) nutritional support and eicosapentaenoic acid in patients with cancer: a systematic review.
Int J Oncol, 28 (2006), pp. 5-23
[22.]
R. Colomer, J.M. Moreno-Nogueira, P.P. García-Luna, P. García-Peris, A. García-de-Lorenzo, A. Zarazaga, et al.
N-3 fatty acids, cancer and cachexia: a systematic review of the literature.
Br J Nutr, 97 (2007), pp. 823-831
[23.]
P.M. Anderson, N.K. Ramsay, X.O. Shu, N. Rydholm, J. Rogosheske, R. Nicklow, et al.
Effect of low-dose oral glutamine on painful stomatitis during bone marrow transplantation.
Bone Marrow Transplant, 22 (1998), pp. 339-344
[24.]
P.R. Schloerb, B.S. Skikne.
Oral and parenteral glutamine in bone marrow transplantation: a randomized, double-blind study.
JPEN J Parenter Enteral Nutr, 23 (1999), pp. 117-122
[25.]
T.M. Coghlin Dickson, R.M. Wong, R.S. Offrin, J.A. Shizuru, L.J. Johnston, W.W. Hu, et al.
Effect of oral glutamine supplementation during bone marrow transplantation.
JPEN J Parenter Enteral Nutr, 24 (2000), pp. 61-66
[26.]
S.A. Brown, A. Goringe, C. Fegan, S.V. Davies, J. Giddings, J.A. Whittaker, et al.
Parenteral glutamine protects hepatic function during bone marrow transplantation.
Bone Marrow Transplant, 22 (1998), pp. 281-284
[27.]
A.P. Goringe, S. Brown, U. Callaghan, J. Rees, S. Jebb, M. Elia, et al.
Glutamine and vitamin E in the treatment of hepatic veno-oclusive disease following high-dose chemotherapy.
Bone Marrow Transplant, 21 (1998), pp. 829-832
[28.]
C. Gómez Candela, R. Castillo, A.I. De Cos, C. Iglesias, M.C. Martín, M.J. Aguado, et al.
Effects of parenteral glutamine in patients submitted to bone marrow transplantation.
Nutr Hosp, 21 (2006), pp. 13-21
[29.]
D.W. Wilmore, P.R. Schloerb, T.R. Ziegler.
Glutamine in the support of patients following bone marrow transplantation.
Curr Opin Clin Nutr Metab Care, 2 (1999), pp. 323-327
[30.]
H.O. Da Gama Torres, E.G. Vilela, A.S. Da Cunha, E.M. Goulart, M.H. Souza, A.C. Aguirre, et al.
Efficacy of glutamine-supplemented parenteral nutrition on short-term survival following allo-SCT: a randomized study.
Bone Marrow Transplant, 41 (2008), pp. 1021-1027
[31.]
R. Pytlík, P. Benes, M. Patorková, E. Chocenská, E. Gregora, B. Procházka, et al.
Standardized parenteral alanyl-glutamine dipeptide supplementation is not beneficial in autologous transplant patients: a randomized, double-blind, placebo controlled study.
Bone Marrow Transplant, 30 (2002), pp. 953-961

SEMICYUC: Sociedad Española de Medicina Intensiva, Crítica y Unidades Coronarias. SENPE: Sociedad Española de Nutrición Parenteral y Enteral.

Copyright © 2011. Sociedad Española de Medicina Intensiva, Critica y Unidades Coronarias (SEMICYUC) and Elsevier España, S.L.
Idiomas
Medicina Intensiva

Suscríbase a la newsletter

Opciones de artículo
Herramientas
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?